Pipeline disappointments may push out the CEO
01/07/25 -"Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 promising pipeline candidates with multi-blockbuster ..."
Pages
75
Language
English
Published on
01/07/25
You may also be interested by these reports :
09/07/25
After integrating the latest figures, we have refined our profitability expectations for the coming years. Given the robust business model, we ...
01/07/25
Back in late-2023, when Sanofi abandoned its 2025 profitability targets to step up its internal R&D efforts, the management had highlighted 12 ...
26/06/25
Downside for 1H25E consensus – FY25E consensus should be fine – Mid-term potential reiterated
24/06/25
Just like Big Pharmas in aggregate, Sanofi’s (Buy; France) shares have gone nowhere over the last two years. After collapsing by c.19% in a day in ...